PEMGARDATM shows continued effectiveness against dominant COVID variants

globenewswire.com

Invivyd, Inc. announced that its investigational monoclonal antibody PEMGARDATM (pemivibart) continues to neutralize dominant SARS-CoV-2 variants KP.3.1.1 and LB.1, with KP.3.1.1 representing 42.2% of circulating variants in late August. The company submitted data to the FDA for updates to the PEMGARDA Healthcare Providers Fact Sheet, highlighting its ongoing efficacy against evolving viral strains.


With a significance score of 5.9, this news ranks in the top 0.3% of today's 28329 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


PEMGARDATM shows continued effectiveness against dominant COVID variants | News Minimalist